Karen Addington, the UK Chief Executive of JDRF, has welcomed three new members to the charity’s Board of Directors.
Jared Chebib, Wilson Leech and Per Lundin have begun their first three-year terms at the charity, which funds research to eradicate type 1 diabetes and its effects for everyone in the UK.
All three Directors have personal experience of life with type 1 diabetes. Wilson and Per have the condition themselves, while Jared is the father of a child who lives with type 1.
At the same time as welcoming the new Directors, JDRF is saying goodbye to Karen Loumansky, who is stepping down as a Board Director after two terms totalling six years.
Jared Chebib, who joins the Board as Treasurer-elect, is currently an Associate Partner at EY and has worked in financial services for more than 25 years.
His daughter’s diagnosis with type 1 gave him a deep personal understanding of, and appreciation for, the importance of JDRF and the research that it supports.
He is keen to make a difference to JDRF’s work to reduce the daily burden of type 1 diabetes on everyone it affects.
Wilson Leech, Executive Chair of management consultants thevaluecircle, is an experienced Chief Executive and Chief Financial Officer, who has worked in financial services throughout his career, most latterly serving as Chief Risk Officer for Northern Trust based in Chicago.
He was diagnosed with type 1 diabetes aged 16, when he was focused on school and careers. Despite the challenges of managing type 1 before widespread blood glucose testing, he went on to study Business Studies at university, and subsequently qualified as an accountant.
Wilson has also previously served on the Board of JDRF in the US and is most interested in technological advancements to help manage type 1 diabetes.
Per Lundin has many years’ experience of medical research, having completed a PhD in Medical Science at the world-famous Karolinska Institutet in Sweden. He is also the co-founder and Chief Operating Officer of biotechnology company Evox Therapeutics, which develops drugs for rare diseases.
Per was diagnosed with type 1 as a young adult, and is passionate about contributing to JDRF’s mission to end type 1 diabetes.
Outgoing Board Director Karen Loumansky supported JDRF in many ways throughout her six-year tenure.
As well as her role on the Board, she also led and served on committees that helped JDRF recruit senior roles and audit its finances.
She also took on numerous cycling challenges for JDRF and encouraged her colleagues at BNY Mellon to do the same.
Karen Addington, UK Chief Executive of JDRF, said: “I’m delighted to welcome Jared, Per and Wilson to our Board of Directors. Their experience and dedication to the cause will be an asset to JDRF as we work to improve the lives of people affected by type 1 diabetes.”
“I would also like to thank Karen for her many years of hard work and support, which have been vital in helping JDRF achieve its aims along the road to a cure.”